Whats new
Whats new.
Baird - Updated Phase 1 Safety/Efficacy HV Data for IMP761 (LAG-3) for Autoimmune; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)
June 23rd 2025
For a copy of this research report please contact your Baird advisor
Whats new
June 23rd 2025
For a copy of this research report please contact your Baird advisor